Download Supplemental Table 1 and Figure Legends

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project

Document related concepts

RNA wikipedia , lookup

Nutriepigenomics wikipedia , lookup

Metagenomics wikipedia , lookup

Epitranscriptome wikipedia , lookup

Long non-coding RNA wikipedia , lookup

Biology and consumer behaviour wikipedia , lookup

History of RNA biology wikipedia , lookup

Epigenetics of diabetes Type 2 wikipedia , lookup

RNA interference wikipedia , lookup

Gene expression programming wikipedia , lookup

X-inactivation wikipedia , lookup

Genome (book) wikipedia , lookup

Oncogenomics wikipedia , lookup

Gene wikipedia , lookup

Polycomb Group Proteins and Cancer wikipedia , lookup

Vectors in gene therapy wikipedia , lookup

Primary transcript wikipedia , lookup

Gene therapy wikipedia , lookup

Non-coding RNA wikipedia , lookup

Therapeutic gene modulation wikipedia , lookup

Gene therapy of the human retina wikipedia , lookup

Microevolution wikipedia , lookup

Artificial gene synthesis wikipedia , lookup

RNA silencing wikipedia , lookup

Site-specific recombinase technology wikipedia , lookup

Epigenetics of human development wikipedia , lookup

NEDD9 wikipedia , lookup

Designer baby wikipedia , lookup

Gene expression profiling wikipedia , lookup

Mir-92 microRNA precursor family wikipedia , lookup

RNA-Seq wikipedia , lookup

Transcript
Supplemental Data Table 1: Patients clinico-pathologic features and CTC status/count data
Approach
Patient ID
used for
CTC
Primary tumor/
Metastatic lesions
n° CTCs/
5 mL blood
ER
status
detection
**
CTC001
CellSearch
203
CTC002
CellSearch
CTC003
PR status
**
HER2
Stage
Line of
(AJCC)
treatment
status
***
Pos/Pos Neg/Neg
Neg/Neg T3N1M0
III
7
Pos/Pos
Pos/Pos
Neg/Neg T2N1M0
I
AdnaGen
*
Pos/Pos
Pos/Pos
Neg/Neg T1N0M0
I
CTC004
CellSearch
13
Pos/Pos Neg/Neg Neg/Neg T2N0M0
II
CTC005
CellSearch
0
Pos/Pos Neg/Neg Neg/Neg T1N0M0
I
CTC006
CellSearch
13
Pos/Pos
Pos/Pos
Neg/Neg T3N0M0
II
CTC007
CellSearch
19
Pos/Pos
Pos/Pos
Neg/Neg T1N1M0
III
* CTC negative by AdnaTest
** evaluated by immunohistochemistry (ER, cut off= 10% positive cells; PR, cut off_10% positive cells) according to
Hammond M.E. et al . J Clin Oncol 2010; 28:2784-95.
*** evaluated by immunohistochemistry and FISH (for HER2 2+ cases)
Supplemental Data Figure 1
Panel A. Pair plots showing correlations between selected samples: Gene expression intensities
obtained from samples containing 100 ng of RNA extracted from MDA-MB-468 cells considered
as benchmarks and correlated with intensities obtained in profiles using decreasing RNA inputs,
respectively 10 ng, 1 ng and 0.5 ng.
Panel B. Eulero-Venn diagrams highlighting the numbers of common and exclusive genes detected
in samples derived from 100 ng of MDA-MB-468 RNA and from 0.5 of RNA from the same cell
line. Gene Ontologies for exclusive genes in each set are reported using character sizes and color
intensities directly proportional the p value for to the gene set enrichment.
Supplemental Data Figure 2
Eulero-Venn diagrams highlighting the numbers of common and exclusive genes detected in
samples derived from 200 MCF7 cells spiked into healthy donor blood (HDB); from HDB not
treated with AdnaWash buffer and HDB samples treated with AdnaWash buffer. Gene Ontologies
for exclusive genes in each set are reported using character sizes and color intensities directly
proportional the p value for to the gene set enrichment.
Supplemental Data Figure 3
Distribution plot of signal mean intensities in gene expression data derived from 5-10-25-50 MDAMB-468 (red dots) or MCF7 (blue dots) cells spiked into healthy donor blood (HDB), from cell-free
HDB (yellow triangles), and from 100 ng of RNA isolated from MCF-7 and MDA-MB-468 cells
(purple and green squares, respectively) profiled with the Illumina Human Whole-Genome DASL
HT.